ArticleTherapeutic innovation & regulatory science2026
Beyond Screen Formats: Towards Context-Aware, Patient-Centric ePRO Design in Clinical Trials.
Article in Therapeutic innovation & regulatory science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lord-Bessen et al. demonstrated that both single-item-per-screen and multiple-items-per-screen ePRO formats are acceptable, with minimal differences in usability and completion time. While format preference may be individual-specific, broader considerations-including patient cognitive load, device type, language complexity, and trial phase-are crucial for context-aware ePRO design. Future research should explore adaptive systems that dynamically adjust format in real time, subgroup analyses for older adults and low digital literacy participants, and language-specific validation. Moving beyond fixed formats toward adaptive, patient-tailored delivery can better align with regulatory priorities for patient-focused drug development, enhancing both participant experience and data integrity.
Indexed as
Identifiers
40858990What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.